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ABSTRACT
Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic 
options. Clinical experiences with anti-EGFR therapies have produced unsatisfactory 
results. The strategies of combined inhibition of EGFR and MEK1/2 could be a 
promising therapeutic option in BTC treatment. Preclinical activity of Panitumumab 
and Trametinib was tested in in vitro (EGI-1, MT-CHC01 and WITT cells) and in in vivo 
(xenograft) BTC models with different K-RAS mutational status. Trametinib reduced 
MAPK phosphorylation in wild type (WT) WITT cells and in both K-RAS mutated 
cells; in EGI-1 was also able to switch off EGFR activation. Panitumumab reduced 
the activation of its target only in EGI-1 cells, and of MAPK only in WITT cells. While 
Trametinib inhibited cell growth in K-RAS mutated cell lines, Panitumumab had no 
effect on proliferation independently by K-RAS status. The addition of Panitumumab 
to Trametinib did not significantly potentiate its anti-proliferative effect also in 
mutated cells. In vivo, Trametinib was able to significantly slow the tumor growth 
in K-RAS mutated xenograft models, but did not have effect on K-RAS WT cells; 
the addition of Panitumumab potentiated the Trametinib efficacy in MT-CHC01 and 
overcame the resistance to the anti-EGFR in WITT cells, in which the monotherapy 
was ineffective. Only in K-RAS mutated xenografts Trametinib alone or in combination 
with Panitumumab significantly decreased Ki67 positive cell fraction and CD31 
angiogenesis markers. In conclusion, this preclinical study provides a rational to plan 
clinical trials assessing the efficacy of Trametinib in K-RAS mutated BTC patients and 
the combination with anti-EGFR in WT BTC patients.
INTRODUCTION
Biliary tract carcinoma (BTC) is a highly and 
heterogeneous malignant epithelial neoplasm arising 
either from the intrahepatic or from the extrahepatic 
biliary tract and gallbladder [1]. Surgical resection is the 
only curative approach, although the majority of patients 
has an advanced unresectable disease at diagnosis; 
further, most patients surgically treated develops tumor 
recurrence [2, 3]. Therefore, it is urgent to find new 
and more effective therapies, possibly based on a better 
understanding of the molecular pathogenesis of these 
tumors.
The expression of EGFR is common in BTC, 
but an overexpression was described in a wide range 
(5–32%) of cases and is more frequently in intrahepatic 
cholangiocarcinoma (ICC) [4–6]. Activating mutations 
of K-RAS and B-RAF can occur in biliary cancers, with 
and incidence ranging from of 8% to 58% and 0 to 22% 
respectively, suggesting that the activation of the RAF/
MAPK signaling pathway may be one of the key event in 
BTC carcinogenesis [7–12].
Recently, several reports demonstrated that anti-
EGFR based therapies combined with chemotherapy 
marginally improve the outcome of these tumors. The 
combination of EGFR antibody, Cetuximab (C) with 
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gemcitabine and oxaliplatin (GEMOX) was tested in 
advanced BTC patients. In the BINGO trial, C-GEMOX 
therapy achieved a median progression-free survival (PFS) 
of 6.1 compared to 5.5 months in GEMOX arm [13, 14]. 
Further trials investigated the potential role of K-RAS 
mutational status as a predictor of response to EGFR 
therapies (Cetuximab or Panitumumab) in BTC. Results 
demonstrated only a marginal benefit in K-RAS wild type 
(WT) patients versus mutated in terms of survival [15, 16]. 
The Vecti-BIL study, which selected K-RAS WT patients 
in a randomized study of GEMOX plus Panitumumab 
(P) vs GEMOX alone, confirmed the marginal role of 
Panitumumab (P) in improving PFS (5.3 months in 
P-GEMOX arm vs 4.4 months in GEMOX arm) and no 
benefit in overall survival (OS) [17].
Recent data on colorectal cancer suggested that one 
of the molecular mechanisms responsible of primary and 
acquired resistance to anti-EGFR therapies is the activation 
of MEK/MAPK [18–20] and that the simultaneous 
inhibition of EGFR and MEK/MAPK could overcome 
this resistance. The inhibition of EGFR downstream 
transducer was already tested in a phase II trial with 
the MEK inhibitor Selumetinib as single agent in BTC 
patients, with an overall response rate (ORR) of 12% [21]. 
Other MEK inhibitors, such as Trametinib and MEK162, 
are under investigation in phase I/II ongoing clinical trials 
in advanced BTC in combination with chemotherapy 
(NCT02042443; NCT01828034, respectively). To date, no 
data are available on the simultaneous inhibition of EGFR 
and MEK/MAPK in BTC.
The strategies of multi-target inhibition focused 
on vertical signaling pathway targeting (combination 
treatment with EGFR and MEK1/2 inhibitors) could also 
synergistically inhibit BTC cancer cell growth.
Here, we investigated the preclinical activity of 
Panitumumab and Trametinib in BTC preclinical models 
harboring different K-RAS mutational status.
RESULTS
Trametinib inhibits in vitro growth of K-RAS 
mutated BTC cell lines
The preclinical activity of the anti-EGFR 
Panitumumab, of the MEK inhibitor Trametinib, and of 
their combination was in vitro assessed using seven BTC 
cell lines expressing basal level of the targets and with 
different K-RAS mutational status.
Two cell lines, the ICC cell line MT-CHC01 and the 
extrahepatic cholangiocarcinoma (ECC) cell line EGI-1 are 
mutated for K-RAS (G12D); the (ECC) WITT and TFK-
1 cells, the gallbladder carcinoma (GBC) TGBC1 cells, 
the (ICC) HUH28 and the ICC mixed to hepatocarcinoma 
KMCH cells were K-RAS WT. IC50 values showed that the 
K-RAS mutated cell lines were sensitive to Trametinib, with 
an IC50 of 3.12 and 6.25 nM, respectively, while the other 
cells were unresponsive. All the cell lines were insensitive to 
Panitumumab (IC50> 5 μM) independently from the K-RAS 
status (Table 1). The combination did not potentiate the 
effect of Trametinib alone in any cell lines (data not shown).
Trametinib inhibits the activation of MAPK in 
vitro
The next step consists in verifying if the EGFR and 
MEK-MAPK transduction pathways were inhibited upon 
Trametinib, Panitumumab, or their combination treatment. 
We decided to use, as experimental in vitro and in vivo 
models, the three tumorigenic cell lines EGI-1, WITT and 
MTCHC01.
Cell lines were treated with 50 nM of Trametinib, 
5 μM of Panitumumab, or their combination for 3 hours. 
Western blot analysis (Figure 1) demonstrated that 
Trametinib was able to switch off the MAPK1,2 activation 
in all the cell lines, independently by K-RAS status. It is 
interesting to note that in EGI-1 cells, Trametinib was 
also able to inhibit EGFR phosphorylation and, even 
less evident, also in WITT cells. Panitumumab reduced 
phospho-EGFR expression in EGI-1 cells and slightly in 
WITT cells. Further, Panitumumab was able to switch the 
MAPK activation in WITT cells.
Trametinib slows tumor growth and inhibits 
angiogenesis in xenograft models of K-RAS 
mutated BTC
Preclinical activity of Trametinib and Panitumumab 
was also evaluated in EGI-1, MT-CHC01 and WITT 
xenografts; 5x106 cells were subcutaneously injected in 
the right flank of 28 mice and four groups (n=7) were 
created. After two/three weeks, tumors volume reached 
100-200 mm3. Mice were then randomized to receive 
different treatments: the first cohort was intraperitoneally 
treated with Panitumumab (200μg/mouse twice a week), 
the second cohort orally received (by gavage) Trametinib 
(0.3 mg/kg/die), another cohort received both drugs, 
and the last cohort was treated with the drug diluents as 
a control. Treatment was stopped at the day 28 for MT-
CHC01 for their aggressiveness, while for the other 
two xenografts, treatment was continued up to 35 days. 
Tumors were calibrated weekly. One day after the last 
drug administration, mice were sacrificed and tumors 
were harvested; curves of tumor volumes showed that 
in xenografts harboring K-RAS mutation, in particular 
in the EGI-1 xenografts, Trametinib drastically slowed 
the tumor growth down (p <0.0001) (Figure 2A and 2D) 
compared to the control arm. In EGI-1, Panitumumab did 
not significantly potentiate the effectiveness of Trametinib, 
which appears to be the real player in vivo. By the way, 
Panitumumab in monotherapy slowed the tumor growth 
in a statistically significant manner compared to the 
control group (p= 0.0001). In MT-CHC01 xenografts, both 
Trametinib and combination reduced tumor growth in a 
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statistically significant manner (p<0.0001) at the end of 
treatment, even if the effect was not marked as in EGI-1 
in vivo model (Figure 2B and 2E). In K-RAS WT WITT 
xenografts, only the drug combination slowed the tumor 
growth (p=0.01) (Figure 2C and 2F).
Effect of Trametinib and/or Panitumumab on 
the expression of MAPK, Ki67, and CD31 in 
BTC in in vivo models
To investigate the mechanism of tumor growth 
inhibition observed in BTC in in vivo models, tumor 
sections derived from xenografts were assessed for the 
expression of MAPK phosphorylation by IHC, and for 
Ki67 e CD31 expression by immunofluorescent analysis. 
As shown in Figure 3, the phosphorylation of MAPK was 
reduced in EGI-1 xenografts both by Panitumumab and 
Trametinib in monotherapy and completely inhibited by 
the drug combination (as in in vitro model). The same 
result was obtained in MT-CHC01 xenografts, but the drug 
combination was not able to completely turn the MAPK 
signaling off. In the WITT xenografts, MAPK activation 
was predominantly inhibited in Trametinib treated mice, 
but a slight effect was shown also in Panitumumab-
treated cohort. The combination arm reflected the effect 
of Trametinib alone.
The evaluation of Ki67 expression in EGI-1 
xenografts (Figure 4A and Supplementary Figure S1) 
demonstrated that all treatments induced a significant 
decrease of tumor proliferation (p <0.0001), although this 
phenomenon is more evident in the presence of Trametinib 
and of the drug combination. The quantification of Ki67 
positive cells showed a 40.62% proliferation index in 
not-treated EGI-1 xenograft model; in xenografts treated 
with Panitumumab and Trametinib in monotherapy 
there was a decrease of Ki67 positive cells at 23.9% 
Figure 1: Western Blot analysis for the evaluation of inhibition of Trametinib and Panitumumab targets. Cell lines were 
treated with 50 nM Trametinib (Tram) and 5 μM Panitumumab (Pan) in monotherapy or in combination (Combo) and the expression of 
p-MAPK, MAPK, p-EGFR, EGFR and Vinculin was investigated.
Table 1: IC50 values of drugs in BTC cell lines with different K-RAS genomic status
CELL LINE TRAM (IC50 nM) PAN (IC50 µM)
EGI-1 (ECC) K-RAS G12D 6.25 nM >5 µM
MT-CHC01 (ICC) K-RAS G12D 3.12 nM >5 µM
WITT (ECC) K-RAS WT >50 nM >5 µM
TFK-1 (ECC) K-RAS WT >50 nM >5 µM
HUH28 (ICC) K-RAS WT >50 nM >5 µM
TGBC1 (GBC) K-RAS WT >50 nM >5 µM
KMCH (ICC MIXED TO HEPATOCARCINOMA) 
K-RAS WT >50 nM >5 µM
IC50: dose of drug which inhibits 50% of the cell growth compared with control calculated for each cell line after 72 
hours of treatment; ECC: extrahepatic cholangiocarcinoma; ICC: intrahepatic cholangiocarcinoma; GBC: gallbladder 
carcinoma; WT: wild type. TRAM: Trametinib; PAN: Panitumumab.
Oncotarget52357www.impactjournals.com/oncotarget
and 18.86% respectively, while the combined treatment 
further decreased the proliferation rate (15.65%)), 
consistent with the significant slow of tumor growth. In 
MT-CHC01 model, Ki67 proliferation index remained 
unchanged in the presence of Panitumumab (37.00% 
in untreated vs 36.64% in Panitumumab treated), and 
decreased to 27.82% and 16.98 with Trametinib and the 
drug combination, respectively (p< 0.0001 in the drug 
combination) (Figure 4B and Supplementary Figure S2). 
Finally, in WITT model, Ki67 index was moderately 
reduced only in Trametinib and in drug combination 
compared with not-treated xenografts (40% in NT vs 
28% of the treated, p=0.01 (Figure 4C and Supplementary 
Figure S3).
To evaluate the antiangiogenic potential of the 
drugs, xenografts were analyzed for CD31 expression. The 
Figure 2: In vivo anti-tumor activity of Trametinib and Panitumumab and their combination in human BTC preclinical 
models. The graphs indicate the median tumor volume (mm3) weekly measured (Panel A: EGI-1; Panel B: MT-CHC01; Panel C: 
WITT): 0 (start of treatment), 7, 14, 21, 28 and 35 days after treatment with Trametinib (Tram 0.3 mg/kg/die), Panitumumab (Pan 200μg/
mouse/twice a week), their combination (Combo), or drug vehicles (NT) (error bars: SD). Seven mice for each arm of treatment in three 
independent experiments were used. Panel D, E and F: representative tumors derived from EGI-1, MT-CHC01 and WITT xenografts, 
respectively.
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Figure 4: Quantification of Ki67 expression on tumor sections derived from EGI-1 A. MT-CHC01 B. and WITT 
C. xenografts treated with Panitumumab (PAN), Trametinib (TRAM) and their combination (COMBO). NT: mice 
treated with drug vehicle.
Figure 3: Representative images of immunohistochemistry analysis for the evaluation of MAPK phosphorylation on 
tumor sections of EGI-1, MT-CHC01 and WITT xenografts treated with Panitumumab (PAN), Trametinib (TRAM), 
their combination (COMBO) and drug vehicle (NT).
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results showed that Trametinib and its combination with 
Panitumumab significantly decreased the vascular density 
in EGI-1 xenografts (p<0.01 and 0.001 respectively), 
whereas Panitumumab as single agent had only a 
moderate effect on tumor angiogenesis (Figure 5A and 
Supplementary Figure S4). In MT-CHC01 xenografts, 
the vessel formation was significantly decreased in all 
treatments (Figure 5B and Supplementary Figure S5) 
(p<0.001 for Trametinib; p< 0.0001 for Panitumumab 
and the drug combination). Finally, in WITT xenografts, 
none of the treatment arms decreased the CD31 expression 
(p>0.01) (Figure 5C and Supplementary Figure S6).
DISCUSSION
The use of anti-EGFR therapies in BTC was 
thoroughly studied in the last years, but results were not 
encouraging. Primary or acquired resistance is the main 
obstacle to overcome; one of the mechanisms of failure 
of anti-EGFR therapies is the presence of downstream 
pathway mutations, namely K-RAS [15]. The employment 
of a K-RAS downstream MEK inhibitor could be the 
key to overcome the resistance to anti-EGFR therapies, 
as demonstrated in lung ad colon cancer [23, 24]. In this 
work, we demonstrated that the MEK inhibitor Trametinib, 
Figure 5: Quantification of CD31 expression on tumor sections derived from EGI-1 A. MT-CHC01 B. and WITT 
C. xenografts treated with Panitumumab (PAN), Trametinib (TRAM) and their combination (COMBO). NT: mice 
treated with drug vehicle.
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as single agent, significantly reduced the proliferation and 
the tumor growth in two K-RAS mutated BTC models and 
is able to contrast the tumor growth in K-RAS WT model 
in association with Panitumumab.
K-RAS is one of the most commonly mutated 
genes in BTCs, but the prevalence of these alterations 
varies widely among studies and is related to ethnicity. 
In a retrospective study of case series of 153 surgically-
resected primary biliary cancers (including 70 ICC, 57 
ECC and 26 GBC) derived from patients of Italian origin, 
the multigene next generation sequencing (NGS) analysis 
demonstrated that 43/153 (28.1%) of patients presented 
K-RAS mutation; in particular, subdividing for histological 
groups, 47.4% of ECC shared K-RAS mutations, while 
ICC and GBC 15.7% and 19.2%, respectively [25]. Our 
group demonstrated in a cohort of 49 BTC patients that 
6.1 % of patients harbored K-RAS mutations [6]. These 
mutations could support a constitutive activation of 
MAPK-MEK pathway, suggesting of being a suitable 
target. To date, the MEK1/2 inhibitor Selumetinib was 
investigated in advanced BTC patients, not selected for 
K-RAS mutations, showing an overall response rate of 
12%, a PFS of 3.7 months and an OS of 9.8 months [21]. 
We showed that, in vitro, Trametinib was able to switch 
off the MAPK1,2 phosphorylation in all the cell lines, 
independently from the basal level of MAPK activation 
and from the K-RAS mutational status. Only in the two 
K-RAS mutated cell lines, EGI-1 and MT-CHC01 cells, 
this inhibition resulted in a reduction of cell growth. 
These data suggest a key role of MAPK/MEK pathway 
in the BTC proliferation process. This is in line with other 
in vitro results described by Jing and colleagues, who 
evaluated the efficacy of Trametinib in a panel of 218 
tumor cell lines, demonstrating a correlation between the 
presence of K-RAS mutations and drug response [26]. On 
the contrary, the K-RAS WT WITT cells are resistant to 
the MEK inhibitor.
Despite the wild type K-RAS mutational status of 
WITT, they are resistant not only to Trametinib, but also 
to Panitumumab in vitro at 72 hrs and up to 144 hrs of 
treatment. In a similar study, in a K-RAS WT BTC cell 
line, the TFK-1, it has been demonstrated that Cetuximab 
decreased in vitro cell growth in a dose dependent manner 
only after twelve days of treatment and in sub-cultured 
cells [27].
The in vivo data reflect those obtained in vitro, 
demonstrating that Trametinib alone is able to slow tumor 
growth inhibiting both proliferation and angiogenesis in 
K-RAS mutated xenografts. Horiuchi and collaborator 
previously showed that the MEK/ERK inhibitor 
U0126 was able to prolong survival in gallbladder 
carcinoma xenograft model with K-RAS mutation [28]. 
Unexpectedly, a moderate but significant efficacy of 
Panitumumab was revealed in EGI-1 K-RAS mutated 
xenograft, suggesting that other mechanisms may be on 
the basis of resistance to anti-EGFR therapies in BTC. 
Ki67 expression was reduced by Trametinib in both 
models, even statistically significant only in EGI-1. The 
inhibition is potentiated by Panitumumab and Trametinib 
combination. Concerning the anti-angiogenetic inhibition, 
CD31 endothelial markers was reduced in all arms of 
treatment in K-RAS mutated xenografts; for EGI-1 model, 
the trend of reduction was also evident in the presence of 
Panitumumab alone, although not significant, due to the 
high variability. On the contrary, in MTCHC01 xenografts, 
Panitumumab significantly reduced angiogenesis, but 
promoted the tumor growth. These data suggest that 
angiogenesis reduction could be an underlying anti-tumor 
mechanism in EGI-1 xenograft model; consequently, 
the two mechanisms are independent and the inhibition 
of angiogenesis is not a sufficient mechanism to inhibit 
growth tumor.
The antiangiogenic role of another MEK inhibitor, 
Selumetinib, was previously reported in lung cancer cells 
resistant to anti-EGFR therapies [29]. Further, Trametinib 
demonstrated an anti-angiogenetic activity also in HUVEC 
cells but not in in vivo model of renal cell carcinoma [30].
In K-RAS WT WITT cell line, the drug combination 
is essential to slow down tumor growth. The angiogenesis 
inhibition is greater in the presence of Panitumumab 
alone, which is able to reduce tumor growth, even if 
not in a statistically significant manner; in contrast, the 
inhibition of angiogenesis is lower in the presence of the 
drug combination that exerted the maximum effect in term 
of tumor growth inhibition. A Ki67 reduction was revealed 
in the combination arm, in line with tumor growth curves.
In conclusion, our preclinical data suggest that 
Trametinib could be a promising alternative target 
therapy for the subgroup of BTC patients harboring 
K-RAS mutations and for K-RAS WT BTC patients with 
primary or acquired resistance to anti-EGFR therapies, 




The extrahepatic cholangiocarcinoma (ECC) cell 
lines EGI-1 and TFK-1 (DMSZ-German collection 
of Microrganisms and Cell Cultures), the intrahepatic 
cholangiocarcinoma (ICC) cell line HuH28 and the 
gallbladder carcinoma (GBC) cell line TGBC1 (Cell Bank, 
RIKEN Bioresource Center Riken Cell Bank, Japan) were 
cultured in RPMI 1640 containing 10% fetal bovine serum 
(FBS) (all from Sigma–Aldrich, St. Louis, MO, USA), 
100 U/mL penicillin and 100 μg/mL streptomycin (P/S) 
(Life Technologies Gathersburg, MD). The ECC WITT 
cells and the ICC mixed to hepatocarcinoma KMCH cells 
(provided by Dr. Andersen, Laboratory of Experimental 
Carcinogenesis, National Institutes of Health, Bethesda, 
Maryland), were cultured in DMEM (Sigma–Aldrich) 
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plus 10% FBS. The authentication of all the cell lines 
was performed by using Cell_ID system (Promega, 
Corporation, Madison, WI, USA) comparing their profile 
with those published on the DMSZ database. The ICC 
cell line MT-CHC01, established in our laboratory [22], 
was cultured in KO-DMEM/F12 with 10% FBS, P/S and 
Hepes buffer.
Drugs
Trametinib was purchased by Sequoia Research 
Products (UK), resuspended in dimethyl-sulfoxide 
(DMSO, Sigma-Aldrich), and stocked in aliquots of (40 
mM) stored at -80° C. Panitumumab (20mg/ml) was 
purchased from Amgen Europe (Netherlands) and stored 
at 4° C. For the in vivo experiments, both drugs were 
diluted in water.
Cell growth assay
Cells (3,000/well) were seeded onto 96-well 
tissue culture plates; after 24 hours, they were treated 
with escalating doses of Panitumumab (5-0.019 μM) 
and Trametinib (50-0.19 nM) as single agent or in 
combination in appropriate complete culture medium 
for other 72 hours. Cell growth was evaluated with the 
Cell Titer-Glo® cell viability assay (Promega). All tests 
were performed in quadruplicate and repeated in three 
independent experiments. IC50 values, (dose of drug able 
to inhibit 50% of the cell growth compared with control) 
were calculated using the CalcuSyn software, based on the 
Chou-Talalay method.
Western blot
Cells were lysed in Cell lysis buffer (Cell Signaling 
Technology, Beverly, USA) and centrifuged at 20,000xg 
for 30 minutes; 20 μg of protein were separated with 
Mini-Protean TGX Precast Gels, 4-20%, then transferred 
using Trans-Blot Turbo on nitrocellulose Midi membranes 
(Biorad). Blots were stained using standard procedures 
and signals were revealed by a chemiluminescence reagent 
(Euroclone, Milan, Italy). Horseradish peroxidase (HRP)-
linked secondary antibodies, anti-phospho-MAPK, anti-
MAPK, anti-phospho EGFR, anti-EGFR, anti-vinculin, 
are from Cell Signaling (Euroclone).
Antitumor activity of panitumumab and 
trametinib in in vivo models of BTC
NOD female mice (Non-Obese Diabetic) /SCID 
(Severe Combined immunodeficient) 4-6 weeks (Charles 
River Laboratory) were maintained under sterile conditions 
in micro-isolator cages at the animal facilities of the 
IRCCS-Candiolo. All animal procedures were approved 
by the Institutional Ethical Committee for Animal 
Experimentation (Fondazione Piemontese per la Ricerca 
sul Cancro) and by the Italian Ministry of Health. In three 
independent experiments, mice were subcutaneously 
injected with EGI-1, WITT, and MT-CHC01 cells (5x106 
cells/mouse) resuspended in 50% (V/V) growth factor–
reduced BD Matrigel basement membrane matrix (BD 
Bioscience). When tumors reached a volume of 100-200 
mm3 (about 2 weeks after injection), animals were divided 
into four arms of treatment: a cohort of seven mice were 
treated daily with Trametinib (0.3 mg/kg/die) by oral 
gavage, another cohort received Panitumumab (200 µg per 
mouse) twice a week intraperitoneally, a cohort received 
the combination of the drugs, while the last cohort of mice 
was treated with the vehicle of the drugs as a control. The 
treatment was prolonged up to 28-35 days.
Subcutaneous xenograft diameters were measured 
every 7 days. At the end of the treatment, mice were 
euthanized, tumor diameters measured, and volumes 
calculated using the following formula: V=A×B2/2 (V= 
tumor volume, A= largest diameter, B= smallest diameter). 
Mean volumes of treated and untreated xenografts were 
compared using thet wo-way Anova statistics, applying 
the Bonferroni test,considering as statistically significant 
a p- value less than 0.05 (confidence interval 95%). 
Tumors were explanted, frozen in OCT or formalin-
fixed, paraffin-embedded (FFPE) and processed for the 
immunohistochemistry and immunofluorescence analyses.
Immunohistochemistry (IHC) and 
immunofluorescence on BTC in in vivo models
For the evaluation of Panitumumab and Trametinib 
effect as single agents or in combination, tissues derived 
from xenografts were stained with anti-Ki67/MIB1 (Dako) 
and anti-CD31 (BecktonDikinson) antibodies, followed 
by incubation with secondary antibody (Invitrogen). Ki67 
expression was evaluated in 10 fields for each section at 
40X by ImageJ; CD31 quantification was performed on 
10 z-stack images for each slide at 20x magnification by 
calculating the positively stained vessel area. Expression 
values of treated and untreated xenografts were compared 
by one-way Anova test, assuming a p-value <0.05 (C.I. 
95%) as statistically significant. For the evaluation of 
MAPK activation, the primary polyclonal antibody anti 
p-MAPK Thr 202/204 was used. The EnVision kit (Dako) 
was used for the detection.
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